Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine

Cancer Research

Volumn 49, Issue 2, 1989, Pages 340-344

  Dorr, Robert T ^a   Liddil, James D ^a   Von Hoff, Daniel D ^b   Soble, Michelle ^a   Osborne, C Kent ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRONINE; MELPHALAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG RESISTANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACRONINE; ALKALOIDS; ANIMAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; INJECTIONS, INTRAPERITONEAL; MICE; SOLUBILITY; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0024496679     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hughes, G. K., Lahey, F. N., Price, J. R., and Webb, L. J. Alkaloids of the Australian Rutaceae. Nature (Lond.), 162:223-224, 1948.
2. Tan, P., and Auersperg, N. Effects of the antineoplastic alkaloid acronycine on the ultrastructure and growth patterns of cultured cells. Cancer Res., 33: 2320-2329, 1973.
3. Low, R. S., and Auersperg, N. Effects of acronycine and of cytochalasin 0 on the division of rat leukemia cells. Exp. Cell Res., 131:15-24, 1981.
4. Dunn, B. P., Gout, P. W., and Beer, C. T. Effects of the antineoplastic alkaloid acronycine on nucleoside uptake and incorporation into nucleic / acids by cultured LS178Y cells. Cancer Res., 33:2310-2319, 1973.
5. Kessel, D. Effects of acronycine on cell-surface properties of murine leukemia cells. Biochem. Pharmacol., 26:1077-1081, 1977.
6. Gout, P. W., Dunn, B. P., and Beer, C. T. Effects of acronycine on nucleic acid synthesis and population growth in mammalian tumor cell cultures. J. Cell. Physiol., 78:127-138, 1971.
7. Bech-Hansen, N. T., Till, J. E., and Long, V. Pleitropic phenotype of colchicine-resistant CHO cells' cross-resistance and collateral sensitivity. J. CeU. Physiol., 88:23-29, 1976.
8. Gerzon, K. Acridone alkaloids: experimental antitumor activity of acrony-cine. In: K. Gerzon and G. Svoboda (eds.), The Alkaloids, pp. 1-28. New York: Academic Press, 1983.
9. Svoboda, G. H., Poore, G. A., Simpson, P. J., and Boder, G. P. Alkaloids of Acronychia baueri Schott I: isolation of the alkaloids and a study of the antitumor and other biological properties of acronycine. J. Pharm. Sci., 55: 758-768, 1966.
10. Scarffe, J. H., Beaumont, A. R., and Crowther, D. Phase I-II evaluation of acronine in patients with multiple myeloma. Cancer Treat. Rep., 67:93-94, 1983.
11. Dorr, R. T., and Liddil, J. D. Development of a parenteral formulation for the antitumor agent acronycine. J. Drug Dev., 1:31-39, 1988.
12. Dorr, R. T., and Fritz, W. L.: Cancer Chemotherapy Handbook, pp. 420-421. Amsterdam: Elsevier/North-Holland Biomedical Press, 1980.
13. Hamburger, A. W., and Salmon, S. E. Primary bioassay of human tumor stem cells. Science (Wash. DC), 197:461-463, 1977.
14. Salmon, S. E., Young, L., Lebowitz, J., Thomson, S., Einsphar, J., Tong, T., and Moon, T. E. Evaluation of an automated image analysis system for counting human tumor colonies. Int. J. Cell Cloning, 2:142-160, 1984.
15. Hamburger, A. W., White, C. P., and Tencer, K. Effect of enzymatic disaggregation on proliferation of human tumor cells in soft agar. J. Natl. Cancer Inst., 68:945-949, 1982.
16. Dorr, R. T., Liddil, J. D., Trent, J. M., and Dalton, W. S. Mitomycin C resistant LI210 cells: association with pleiotropic drug resistance. Biochem. Pharmacol., 36:3115-3120, 1987.
17. Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H., and Cress, A. E.: Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res., 46:5125-5130, 1986.
18. Beck, W. T., Mueller, T. J., and Tanzer, L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res., 39:2070-2076, 1979.
19. Ling, V., and Thompson, L. H. Reduced permeability in Chinese hamster ovary cells as a mechanism of resistance to colchicine. J. Cell. Physiol., 83: 103-106, 1975.
20. Valeriote, F., Lynch, R., Berger, N. A., White, E., and Coulter, D. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer-agents. J. Natl Cancer Inst, 66:1083-1088, 1981.
21. Corbett, T. H., Griswold, D. P., Jr., Roberts, B. J., Peckham, J. C., and Schabel, F. M. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer (Phila.), 40:2660-2680, 1977.
22. Osborne, C. K., Hobbs, K., and Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mouse. Cancer Res., 45:584-590, 1985.
23. Mantel, N. Evaluation of survival data and two new rank order statistics in its consideration. Cancer Chemother. Rep., 50:163-189, 1966.
24. Metzler, C. M., Elfring, G. L., and McEwen, A. J.: A package of computer programs for pharmacokinetic modeling. Biometrics, 30:512-513, 1974.
25. Blanchard, J., Sawchuk, R., and Brodie, B. B. (eds.). Principles and Perspectives in Drug Bioavailability. Basel: S. Karger AG, 1979.